Chengdu Easton Biopharmaceuticals Co., Ltd. (SHA:688513)
China · Delayed Price · Currency is CNY 57.95
+2.59 (4.68%)
At close: Mar 6, 2026
SHA:688513 Revenue
In the year 2025, Chengdu Easton Biopharmaceuticals had annual revenue of 1.33B CNY, down -1.36%. Chengdu Easton Biopharmaceuticals had revenue of 312.26M in the quarter ending December 31, 2025, with 0.79% growth.
Revenue
1.33B
Revenue Growth
-1.36%
P/S Ratio
7.59
Revenue / Employee
874.77K
Employees
1,522
Market Cap
10.10B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.33B | -18.36M | -1.36% |
| Dec 31, 2024 | 1.35B | 232.63M | 20.82% |
| Dec 31, 2023 | 1.12B | -53.39M | -4.56% |
| Dec 31, 2022 | 1.17B | 147.58M | 14.43% |
| Dec 31, 2021 | 1.02B | 101.02M | 10.96% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Chengzhi | 11.53B |
| China Resources Boya Bio-pharmaceutical Group Co.,Ltd | 1.96B |
| Jiangsu Sinopep-Allsino Biopharmaceutical | 1.94B |
| Aurisco Pharmaceutical | 1.62B |
| Liaoning Chengda Biotechnology | 1.39B |
| Shanghai Medicilon | 1.08B |
| Hualan Biological Vaccine | 976.44M |
| Bio-Thera Solutions | 933.69M |